The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Novo Nordisk’s oral Wegovy gets FDA approval, but rising costs and competition threaten profits. Learn why analysts rate NVO ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

The FDA has approved the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for weight loss and to reduce the risk ...

A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic ...

The FDA approved the first oral GLP-1 for lowering body weight according to a press release from Novo Nordisk. Oral ...

Scientists are discovering that the oral microbiome—home to hundreds of species of bacteria and fungi—may help predict ...

Oral bacteria that migrate to the gut can generate metabolites that reach the brain and accelerate Parkinson’s disease.

An oral formulation of semaglutide has received United States Food and Drug Administration approval for a new drug or biologic under the Prescription Drug User Fee Act. The University of Alabama at ...

High levels of the periodontal bacterium Fusobacterium nucleatum may be associated with more severe disability in people with multiple sclerosis.